Loperamide (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Loperamide" in English language version.

refsWebsite

Global rank English rank

44web.archive.org

1^st place

28nih.gov

4^th place

18doi.org

2^nd place

10books.google.com

3^rd place

10fda.gov

447^th place

338^th place

6semanticscholar.org

11^th place

8^th place

5drugs.com

399^th place

333^rd place

3nhs.uk

1,989^th place

1,528^th place

3espacenet.com

800^th place

676^th place

3worldcat.org

5^th place

2handle.net

102^nd place

76^th place

2clincalc.com

3,912^th place

2,496^th place

2epocrates.com

low place

2washingtonpost.com

34^th place

27^th place

1in.gov.br

3,151^st place

5,932^nd place

1tga.gov.au

3,984^th place

2,622^nd place

1cancer.gov

1,684^th place

1,350^th place

1rxlist.com

7,927^th place

6,815^th place

1essentialdrugs.org

low place

1drugbank.ca

4,294^th place

6,357^th place

1aspetjournals.org

6,663^rd place

5,792^nd place

1agingbraincare.org

low place

1ebi.ac.uk

5,849^th place

7,886^th place

1justia.com

696^th place

428^th place

1who.int

195^th place

302^nd place

1thefreelibrary.com

518^th place

331^st place

1archive.org

6^th place

1uni-frankfurt.de

4,572^nd place

7,417^th place

1archive.today

14^th place

1federalregister.gov

2,474^th place

1,469^th place

1nice.org.uk

3,258^th place

2,666^th place

agingbraincare.org

"Anticholinergic Cognitive Burden Scale" (PDF). Archived from the original (PDF) on 7 March 2018. Retrieved 23 September 2017.

archive.org

Rathbone MJ, Hadgraft J, Roberts MS (2002). "The Zydis Oral Fast-Dissolving Dosage Form". Modified-Release Drug Delivery Technology. CRC Press. pp. 200. ISBN 9780824708696. Retrieved 26 August 2014.

archive.today

Mullen F (3 November 1982). "FR Doc. 82-30264" (PDF). Federal Register. DEA. Archived from the original (PDF) on 27 June 2023. Retrieved 26 June 2023.

aspetjournals.org

dmd.aspetjournals.org

Kalgutkar AS, Nguyen HT (September 2004). "Identification of an N-methyl-4-phenylpyridinium-like metabolite of the antidiarrheal agent loperamide in human liver microsomes: underlying reason(s) for the lack of neurotoxicity despite the bioactivation event". Drug Metabolism and Disposition. 32 (9): 943–52. PMID 15319335. Archived from the original on 8 September 2017.

books.google.com

Patrick GL (2013). An introduction to medicinal chemistry (Fifth ed.). Oxford: Oxford University Press. p. 644. ISBN 9780199697397. Archived from the original on 14 January 2023. Retrieved 17 December 2020.
Hamilton RJ (2013). Tarascon pocket pharmacopoeia (14 ed.). [Sudbury, Mass.]: Jones & Bartlett Learning. p. 217. ISBN 9781449673611. Archived from the original on 5 March 2016.
Miftahof R (2009). Mathematical Modeling and Simulation in Enteric Neurobiology. World Scientific. p. 18. ISBN 9789812834812. Archived from the original on 28 July 2017.
Benson A, Chakravarthy A, Hamilton SR, Elin S, eds. (2013). Cancers of the Colon and Rectum: A Multidisciplinary Approach to Diagnosis and Management. Demos Medical Publishing. p. 225. ISBN 9781936287581. Archived from the original on 8 September 2017.
Zuckerman JN (2012). Principles and Practice of Travel Medicine. John Wiley & Sons. p. 203. ISBN 9781118392089. Archived from the original on 8 September 2017.
Lemke TL, Williams DA (2008). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. p. 675. ISBN 9780781768795. Archived from the original on 8 September 2017.
Florey K (1991). Profiles of Drug Substances, Excipients and Related Methodology, Volume 19. Academic Press. p. 342. ISBN 9780080861142. Archived from the original on 14 January 2023. Retrieved 18 May 2016.
Consolidated List of Products Whose Consumption And/or Sale Have Been Banned, Withdrawn, Severely Restricted Or Not Approved by Governments, 8th Issue. United Nations. 2003. pp. 130–131. ISBN 978-92-1-130230-1. Archived from the original on 8 September 2017.
Rathbone MJ, Hadgraft J, Roberts MS (2002). "The Zydis Oral Fast-Dissolving Dosage Form". Modified-Release Drug Delivery Technology. CRC Press. pp. 200. ISBN 9780824708696. Retrieved 26 August 2014.
Mediators and Drugs in Gastrointestinal Motility II: Endogenous and Exogenous Agents. Springer Science & Business Media. 6 December 2012. pp. 290–. ISBN 978-3-642-68474-6. Archived from the original on 12 January 2023. Retrieved 18 May 2016.

cancer.gov

"loperamide hydrochloride". NCI Drug Dictionary. 2 February 2011. Archived from the original on 7 September 2015. Retrieved 26 August 2015.

clincalc.com

"The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
"Loperamide Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.

doi.org

Litovitz T, Clancy C, Korberly B, Temple AR, Mann KV (1997). "Surveillance of loperamide ingestions: an analysis of 216 poison center reports". Journal of Toxicology. Clinical Toxicology. 35 (1): 11–9. doi:10.3109/15563659709001159. PMID 9022646.
Li ST, Grossman DC, Cummings P (2007). "Loperamide therapy for acute diarrhea in children: systematic and meta-analysis". PLOS Medicine. 4 (3): e98. doi:10.1371/journal.pmed.0040098. PMC 1831735. PMID 17388664.
Einarson A, Mastroiacovo P, Arnon J, Ornoy A, Addis A, Malm H, et al. (March 2000). "Prospective, controlled, multicentre study of loperamide in pregnancy". Canadian Journal of Gastroenterology. 14 (3): 185–7. doi:10.1155/2000/957649. PMID 10758415.
Dufek MB, Knight BM, Bridges AS, Thakker DR (March 2013). "P-glycoprotein increases portal bioavailability of loperamide in mouse by reducing first-pass intestinal metabolism". Drug Metabolism and Disposition. 41 (3): 642–50. doi:10.1124/dmd.112.049965. PMID 23288866. S2CID 11014783.
Upton RN (August 2007). "Cerebral uptake of drugs in humans". Clinical and Experimental Pharmacology & Physiology. 34 (8): 695–701. doi:10.1111/j.1440-1681.2007.04649.x. PMID 17600543. S2CID 41591261.
Antoniou T, Juurlink DN (June 2017). "Loperamide abuse". CMAJ. 189 (23): E803. doi:10.1503/cmaj.161421. PMC 5468105. PMID 28606977.
Sadeque AJ, Wandel C, He H, Shah S, Wood AJ (September 2000). "Increased drug delivery to the brain by P-glycoprotein inhibition". Clinical Pharmacology and Therapeutics. 68 (3): 231–7. doi:10.1067/mcp.2000.109156. PMID 11014404. S2CID 38467170.
Nakamura H, Ishii K, Yokoyama Y, Motoyoshi S, Suzuki K, Sekine Y, et al. (November 1982). "[Physical dependence on loperamide hydrochloride in mice and rats]". Yakugaku Zasshi (in Japanese). 102 (11): 1074–85. doi:10.1248/yakushi1947.102.11_1074. PMID 6892112.
Stokbroekx RA, Vandenberk J, Van Heertum AH, Van Laar GM, Van der Aa MJ, Van Bever WF, et al. (July 1973). "Synthetic antidiarrheal agents. 2,2-Diphenyl-4-(4'-aryl-4'-hydroxypiperidino)butyramides". Journal of Medicinal Chemistry. 16 (7): 782–786. doi:10.1021/jm00265a009. PMID 4725924.
Van Rompay J, Carter JE (January 1990). Florey K (ed.). "Loperamide hydrochloride". Analytical Profiles of Drug Substances. 19. Academic Press: 341–365. doi:10.1016/s0099-5428(08)60372-x. ISBN 9780122608193.
Mainguet P, Fiasse R (July 1977). "Double-blind placebo-controlled study of loperamide (Imodium) in chronic diarrhoea caused by ileocolic disease or resection". Gut. 18 (7): 575–9. doi:10.1136/gut.18.7.575. PMC 1411573. PMID 326642.
Connelly D (April 2017). "A breakdown of the over-the-counter medicines market in Britain in 2016". The Pharmaceutical Journal. 298 (7900). Royal Pharmaceutical Society. doi:10.1211/pj.2017.20202662. ISSN 2053-6186.
MacDonald R, Heiner J, Villarreal J, Strote J (May 2015). "Loperamide dependence and abuse". BMJ Case Reports. 2015: bcr2015209705. doi:10.1136/bcr-2015-209705. PMC 4434293. PMID 25935922.
Dierksen J, Gonsoulin M, Walterscheid JP (December 2015). "Poor Man's Methadone: A Case Report of Loperamide Toxicity". The American Journal of Forensic Medicine and Pathology. 36 (4): 268–70. doi:10.1097/PAF.0000000000000201. PMID 26355852. S2CID 19635919.
Stanciu CN, Gnanasegaram SA (2017). "Loperamide, the "Poor Man's Methadone": Brief Review". Journal of Psychoactive Drugs. 49 (1): 18–21. doi:10.1080/02791072.2016.1260188. PMID 27918873. S2CID 31713818.
Feldman R, Everton E (November 2020). "National assessment of pharmacist awareness of loperamide abuse and ability to restrict sale if abuse is suspected". Journal of the American Pharmacists Association. 60 (6): 868–873. doi:10.1016/j.japh.2020.05.021. PMID 32641253. S2CID 220436708.
Eggleston W, Clark KH, Marraffa JM (January 2017). "Loperamide Abuse Associated With Cardiac Dysrhythmia and Death". Annals of Emergency Medicine. 69 (1): 83–86. doi:10.1016/j.annemergmed.2016.03.047. PMID 27140747.
Mukarram O, Hindi Y, Catalasan G, Ward J (2016). "Loperamide Induced Torsades de Pointes: A Case Report and Review of the Literature". Case Reports in Medicine. 2016: 4061980. doi:10.1155/2016/4061980. PMC 4775784. PMID 26989420.

drugbank.ca

"DrugBank: Loperamide". Archived from the original on 10 May 2016. Retrieved 14 May 2016.

drugs.com

Drugs.com International brands for loperamide Archived 23 September 2015 at the Wayback Machine Page accessed 4 September 2015
"Loperamide Hydrochloride". The American Society of Health-System Pharmacists. Archived from the original on 7 September 2015. Retrieved 25 August 2015.
"Loperamide use while Breastfeeding". Archived from the original on 8 September 2015. Retrieved 26 August 2015.
"Loperamide". Archived from the original on 20 May 2016. Retrieved 14 May 2016.
"Loperamide Hydrochloride Drug Information, Professional". Archived from the original on 3 May 2016. Retrieved 14 May 2016.

ebi.ac.uk

"Compound Report Card". Archived from the original on 11 August 2016. Retrieved 23 June 2016.

epocrates.com

online.epocrates.com

"loperamide adverse reactions". Archived from the original on 1 November 2018. Retrieved 14 May 2016.
"Loperamide Drug Interactions - Epocrates Online". online.epocrates.com. Archived from the original on 1 November 2018. Retrieved 5 November 2020.

espacenet.com

worldwide.espacenet.com

US 3714159, Janssen PA, Niemegeers CJ, issued 1973
US 3884916, Janssen PA, Niemegeers CJ, issued 1975
US patent 5612054, Jeffrey L. Garwin, "Pharmaceutical compositions for treating gastrointestinal distress", issued 1997-03-18, assigned to McNeil-PPC, Inc.

essentialdrugs.org

"E-DRUG: Chlormezanone". Essentialdrugs.org. Archived from the original on 26 July 2011.

fda.gov

accessdata.fda.gov

"Imodium label" (PDF). U.S. Food and Drug Administration (FDA). Archived (PDF) from the original on 23 April 2014. Retrieved 21 April 2014.
"Drugs@FDA: FDA Approved Drug Products". U.S. Food and Drug Administration (FDA). Archived from the original on 6 May 2016. Retrieved 14 May 2016.
"Drugs@FDA: FDA Approved Drug Products". U.S. Food and Drug Administration (FDA). Archived from the original on 6 May 2016. Retrieved 14 May 2016.
"IMODIUM FDA Application No.(NDA) 017694". U.S. Food and Drug Administration (FDA). 1976. Archived from the original on 13 August 2014. Retrieved 5 September 2014.
"IMODIUM A-D FDA Application No.(NDA) 019487". U.S. Food and Drug Administration (FDA). 1988. Archived from the original on 13 August 2014. Retrieved 5 September 2014.
"IMODIUM MULTI-SYMPTOM RELIEF FDA Application No.(NDA) 020606". U.S. Food and Drug Administration (FDA). 1997. Archived from the original on 13 August 2014. Retrieved 5 September 2014.
"Drug Approval Package: Imodium Advanced (Loperamide HCI and Simethicone NDA #21-140". U.S. Food and Drug Administration (FDA). 24 December 1999. Archived from the original on 2 September 2023. Retrieved 16 December 2020.

fda.gov

"Safety Alerts for Human Medical Products - Loperamide (Imodium): Drug Safety Communication - Serious Heart Problems With High Doses From Abuse and Misuse". U.S. Food and Drug Administration (FDA). Archived from the original on 11 June 2016. Retrieved 12 June 2016.
"Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers". U.S. Food and Drug Administration (FDA). Archived from the original on 10 May 2016. Retrieved 14 May 2016.
Office of the Commissioner. "Safety Alerts for Human Medical Products - Imodium (loperamide) for Over-the-Counter Use: Drug Safety Communication - FDA Limits Packaging To Encourage Safe Use". U.S. Food and Drug Administration (FDA). Archived from the original on 8 April 2018. Retrieved 2 February 2018.

federalregister.gov

archives.federalregister.gov

Mullen F (3 November 1982). "FR Doc. 82-30264" (PDF). Federal Register. DEA. Archived from the original (PDF) on 27 June 2023. Retrieved 26 June 2023.

handle.net

hdl.handle.net

World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
World Health Organization (2014). The selection and use of essential medicines: report of the WHO Expert Committee, 2013 (including the 18th WHO model list of essential medicines and the 4th WHO model list of essential medicines for children). Geneva: World Health Organization. hdl:10665/112729. ISBN 9789241209854. ISSN 0512-3054. WHO technical report series;985.

in.gov.br

Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.

justia.com

law.justia.com

McNeil-PPC, Inc., Plaintiff, v. L. Perrigo Company, and Perrigo Company, Defendants, 207 F. Supp. 2d 356 (E.D. Pa. 25 June 2002).

nhs.uk

"About loperamide". nhs.uk. 11 April 2024.
"Loperamide: a medicine used to treat diarrhoea". National Health Service. 20 December 2018. Retrieved 7 October 2023.
"Medicines information links - NHS Choices". Archived from the original on 10 January 2014. Retrieved 14 May 2016.

nice.org.uk

bnf.nice.org.uk

"BNF is only available in the UK".

nih.gov

pubmed.ncbi.nlm.nih.gov

Hanauer SB (Winter 2008). "The role of loperamide in gastrointestinal disorders". Reviews in Gastroenterological Disorders. 8 (1): 15–20. PMID 18477966.
Litovitz T, Clancy C, Korberly B, Temple AR, Mann KV (1997). "Surveillance of loperamide ingestions: an analysis of 216 poison center reports". Journal of Toxicology. Clinical Toxicology. 35 (1): 11–9. doi:10.3109/15563659709001159. PMID 9022646.
Li ST, Grossman DC, Cummings P (2007). "Loperamide therapy for acute diarrhea in children: systematic and meta-analysis". PLOS Medicine. 4 (3): e98. doi:10.1371/journal.pmed.0040098. PMC 1831735. PMID 17388664.
Einarson A, Mastroiacovo P, Arnon J, Ornoy A, Addis A, Malm H, et al. (March 2000). "Prospective, controlled, multicentre study of loperamide in pregnancy". Canadian Journal of Gastroenterology. 14 (3): 185–7. doi:10.1155/2000/957649. PMID 10758415.
Dufek MB, Knight BM, Bridges AS, Thakker DR (March 2013). "P-glycoprotein increases portal bioavailability of loperamide in mouse by reducing first-pass intestinal metabolism". Drug Metabolism and Disposition. 41 (3): 642–50. doi:10.1124/dmd.112.049965. PMID 23288866. S2CID 11014783.
Kalgutkar AS, Nguyen HT (September 2004). "Identification of an N-methyl-4-phenylpyridinium-like metabolite of the antidiarrheal agent loperamide in human liver microsomes: underlying reason(s) for the lack of neurotoxicity despite the bioactivation event". Drug Metabolism and Disposition. 32 (9): 943–52. PMID 15319335. Archived from the original on 8 September 2017.
Upton RN (August 2007). "Cerebral uptake of drugs in humans". Clinical and Experimental Pharmacology & Physiology. 34 (8): 695–701. doi:10.1111/j.1440-1681.2007.04649.x. PMID 17600543. S2CID 41591261.
Antoniou T, Juurlink DN (June 2017). "Loperamide abuse". CMAJ. 189 (23): E803. doi:10.1503/cmaj.161421. PMC 5468105. PMID 28606977.
Sadeque AJ, Wandel C, He H, Shah S, Wood AJ (September 2000). "Increased drug delivery to the brain by P-glycoprotein inhibition". Clinical Pharmacology and Therapeutics. 68 (3): 231–7. doi:10.1067/mcp.2000.109156. PMID 11014404. S2CID 38467170.
Yanagita T, Miyasato K, Sato J (1979). "Dependence potential of loperamide studied in rhesus monkeys". NIDA Research Monograph. 27: 106–13. PMID 121326.
Nakamura H, Ishii K, Yokoyama Y, Motoyoshi S, Suzuki K, Sekine Y, et al. (November 1982). "[Physical dependence on loperamide hydrochloride in mice and rats]". Yakugaku Zasshi (in Japanese). 102 (11): 1074–85. doi:10.1248/yakushi1947.102.11_1074. PMID 6892112.
Stokbroekx RA, Vandenberk J, Van Heertum AH, Van Laar GM, Van der Aa MJ, Van Bever WF, et al. (July 1973). "Synthetic antidiarrheal agents. 2,2-Diphenyl-4-(4'-aryl-4'-hydroxypiperidino)butyramides". Journal of Medicinal Chemistry. 16 (7): 782–786. doi:10.1021/jm00265a009. PMID 4725924.
Schuermans V, Van Lommel R, Dom J, Brugmans J (1974). "Loperamide (R 18 553), a novel type of antidiarrheal agent. Part 6: Clinical pharmacology. Placebo-controlled comparison of the constipating activity and safety of loperamide, diphenoxylate and codeine in normal volunteers". Arzneimittelforschung. 24 (10): 1653–7. PMID 4611432.
Mainguet P, Fiasse R (July 1977). "Double-blind placebo-controlled study of loperamide (Imodium) in chronic diarrhoea caused by ileocolic disease or resection". Gut. 18 (7): 575–9. doi:10.1136/gut.18.7.575. PMC 1411573. PMID 326642.
Baker DE (2007). "Loperamide: a pharmacological review". Reviews in Gastroenterological Disorders. 7 (Suppl 3): S11-8. PMID 18192961.
MacDonald R, Heiner J, Villarreal J, Strote J (May 2015). "Loperamide dependence and abuse". BMJ Case Reports. 2015: bcr2015209705. doi:10.1136/bcr-2015-209705. PMC 4434293. PMID 25935922.
Dierksen J, Gonsoulin M, Walterscheid JP (December 2015). "Poor Man's Methadone: A Case Report of Loperamide Toxicity". The American Journal of Forensic Medicine and Pathology. 36 (4): 268–70. doi:10.1097/PAF.0000000000000201. PMID 26355852. S2CID 19635919.
Stanciu CN, Gnanasegaram SA (2017). "Loperamide, the "Poor Man's Methadone": Brief Review". Journal of Psychoactive Drugs. 49 (1): 18–21. doi:10.1080/02791072.2016.1260188. PMID 27918873. S2CID 31713818.
Feldman R, Everton E (November 2020). "National assessment of pharmacist awareness of loperamide abuse and ability to restrict sale if abuse is suspected". Journal of the American Pharmacists Association. 60 (6): 868–873. doi:10.1016/j.japh.2020.05.021. PMID 32641253. S2CID 220436708.
Eggleston W, Clark KH, Marraffa JM (January 2017). "Loperamide Abuse Associated With Cardiac Dysrhythmia and Death". Annals of Emergency Medicine. 69 (1): 83–86. doi:10.1016/j.annemergmed.2016.03.047. PMID 27140747.
Mukarram O, Hindi Y, Catalasan G, Ward J (2016). "Loperamide Induced Torsades de Pointes: A Case Report and Review of the Literature". Case Reports in Medicine. 2016: 4061980. doi:10.1155/2016/4061980. PMC 4775784. PMID 26989420.

ncbi.nlm.nih.gov

Li ST, Grossman DC, Cummings P (2007). "Loperamide therapy for acute diarrhea in children: systematic and meta-analysis". PLOS Medicine. 4 (3): e98. doi:10.1371/journal.pmed.0040098. PMC 1831735. PMID 17388664.
Antoniou T, Juurlink DN (June 2017). "Loperamide abuse". CMAJ. 189 (23): E803. doi:10.1503/cmaj.161421. PMC 5468105. PMID 28606977.
Mainguet P, Fiasse R (July 1977). "Double-blind placebo-controlled study of loperamide (Imodium) in chronic diarrhoea caused by ileocolic disease or resection". Gut. 18 (7): 575–9. doi:10.1136/gut.18.7.575. PMC 1411573. PMID 326642.
MacDonald R, Heiner J, Villarreal J, Strote J (May 2015). "Loperamide dependence and abuse". BMJ Case Reports. 2015: bcr2015209705. doi:10.1136/bcr-2015-209705. PMC 4434293. PMID 25935922.
Mukarram O, Hindi Y, Catalasan G, Ward J (2016). "Loperamide Induced Torsades de Pointes: A Case Report and Review of the Literature". Case Reports in Medicine. 2016: 4061980. doi:10.1155/2016/4061980. PMC 4775784. PMID 26989420.

dailymed.nlm.nih.gov

"Loperamide hydrochloride capsule". DailyMed. 30 September 2022. Archived from the original on 14 September 2023. Retrieved 8 January 2024.
"Imodium (Loperamide Hydrochloride) Capsule". DailyMed. NIH. Archived from the original on 13 April 2010.

rxlist.com

"rxlist.com". 2005. Archived from the original on 27 November 2012.

semanticscholar.org

api.semanticscholar.org

Dufek MB, Knight BM, Bridges AS, Thakker DR (March 2013). "P-glycoprotein increases portal bioavailability of loperamide in mouse by reducing first-pass intestinal metabolism". Drug Metabolism and Disposition. 41 (3): 642–50. doi:10.1124/dmd.112.049965. PMID 23288866. S2CID 11014783.
Upton RN (August 2007). "Cerebral uptake of drugs in humans". Clinical and Experimental Pharmacology & Physiology. 34 (8): 695–701. doi:10.1111/j.1440-1681.2007.04649.x. PMID 17600543. S2CID 41591261.
Sadeque AJ, Wandel C, He H, Shah S, Wood AJ (September 2000). "Increased drug delivery to the brain by P-glycoprotein inhibition". Clinical Pharmacology and Therapeutics. 68 (3): 231–7. doi:10.1067/mcp.2000.109156. PMID 11014404. S2CID 38467170.
Dierksen J, Gonsoulin M, Walterscheid JP (December 2015). "Poor Man's Methadone: A Case Report of Loperamide Toxicity". The American Journal of Forensic Medicine and Pathology. 36 (4): 268–70. doi:10.1097/PAF.0000000000000201. PMID 26355852. S2CID 19635919.
Stanciu CN, Gnanasegaram SA (2017). "Loperamide, the "Poor Man's Methadone": Brief Review". Journal of Psychoactive Drugs. 49 (1): 18–21. doi:10.1080/02791072.2016.1260188. PMID 27918873. S2CID 31713818.
Feldman R, Everton E (November 2020). "National assessment of pharmacist awareness of loperamide abuse and ability to restrict sale if abuse is suspected". Journal of the American Pharmacists Association. 60 (6): 868–873. doi:10.1016/j.japh.2020.05.021. PMID 32641253. S2CID 220436708.

tga.gov.au

"Prescribing medicines in pregnancy database". Australian Government. 3 March 2014. Archived from the original on 8 April 2014. Retrieved 22 April 2014.

thefreelibrary.com

"Scherer announces launch of another product utilizing its Zydis technology". PR Newswire Association LLC. 9 November 1993. Archived from the original on 30 August 2014. Retrieved 30 August 2014.

uni-frankfurt.de

aktuelles.uni-frankfurt.de

"Anti-diarrhoea drug drives cancer cells to cell death – Aktuelles aus der Goethe-Universität Frankfurt". aktuelles.uni-frankfurt.de. Archived from the original on 23 December 2020.

washingtonpost.com

Guarino B (4 May 2016). "Abuse of diarrhea medicine you know well is alarming physicians". Washington Post. Archived from the original on 6 May 2016. Retrieved 6 May 2016.
McGinley L (30 January 2018). "FDA wants to curb abuse of Imodium, 'the poor man's methadone'". Washington Post. ISSN 0190-8286. Archived from the original on 30 January 2018. Retrieved 30 January 2018.

web.archive.org

Drugs.com International brands for loperamide Archived 23 September 2015 at the Wayback Machine Page accessed 4 September 2015
Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
"Loperamide hydrochloride capsule". DailyMed. 30 September 2022. Archived from the original on 14 September 2023. Retrieved 8 January 2024.
"Loperamide Hydrochloride". The American Society of Health-System Pharmacists. Archived from the original on 7 September 2015. Retrieved 25 August 2015.
"Prescribing medicines in pregnancy database". Australian Government. 3 March 2014. Archived from the original on 8 April 2014. Retrieved 22 April 2014.
"Loperamide use while Breastfeeding". Archived from the original on 8 September 2015. Retrieved 26 August 2015.
"loperamide hydrochloride". NCI Drug Dictionary. 2 February 2011. Archived from the original on 7 September 2015. Retrieved 26 August 2015.
Patrick GL (2013). An introduction to medicinal chemistry (Fifth ed.). Oxford: Oxford University Press. p. 644. ISBN 9780199697397. Archived from the original on 14 January 2023. Retrieved 17 December 2020.
Hamilton RJ (2013). Tarascon pocket pharmacopoeia (14 ed.). [Sudbury, Mass.]: Jones & Bartlett Learning. p. 217. ISBN 9781449673611. Archived from the original on 5 March 2016.
"The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
"Loperamide". Archived from the original on 20 May 2016. Retrieved 14 May 2016.
Miftahof R (2009). Mathematical Modeling and Simulation in Enteric Neurobiology. World Scientific. p. 18. ISBN 9789812834812. Archived from the original on 28 July 2017.
Benson A, Chakravarthy A, Hamilton SR, Elin S, eds. (2013). Cancers of the Colon and Rectum: A Multidisciplinary Approach to Diagnosis and Management. Demos Medical Publishing. p. 225. ISBN 9781936287581. Archived from the original on 8 September 2017.
Zuckerman JN (2012). Principles and Practice of Travel Medicine. John Wiley & Sons. p. 203. ISBN 9781118392089. Archived from the original on 8 September 2017.
"Imodium label" (PDF). U.S. Food and Drug Administration (FDA). Archived (PDF) from the original on 23 April 2014. Retrieved 21 April 2014.
"loperamide adverse reactions". Archived from the original on 1 November 2018. Retrieved 14 May 2016.
"Safety Alerts for Human Medical Products - Loperamide (Imodium): Drug Safety Communication - Serious Heart Problems With High Doses From Abuse and Misuse". U.S. Food and Drug Administration (FDA). Archived from the original on 11 June 2016. Retrieved 12 June 2016.
"rxlist.com". 2005. Archived from the original on 27 November 2012.
"Drugs@FDA: FDA Approved Drug Products". U.S. Food and Drug Administration (FDA). Archived from the original on 6 May 2016. Retrieved 14 May 2016.
"Imodium (Loperamide Hydrochloride) Capsule". DailyMed. NIH. Archived from the original on 13 April 2010.
"E-DRUG: Chlormezanone". Essentialdrugs.org. Archived from the original on 26 July 2011.
"Medicines information links - NHS Choices". Archived from the original on 10 January 2014. Retrieved 14 May 2016.
"Drugs@FDA: FDA Approved Drug Products". U.S. Food and Drug Administration (FDA). Archived from the original on 6 May 2016. Retrieved 14 May 2016.
"Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers". U.S. Food and Drug Administration (FDA). Archived from the original on 10 May 2016. Retrieved 14 May 2016.
"Loperamide Drug Interactions - Epocrates Online". online.epocrates.com. Archived from the original on 1 November 2018. Retrieved 5 November 2020.
"DrugBank: Loperamide". Archived from the original on 10 May 2016. Retrieved 14 May 2016.
"Loperamide Hydrochloride Drug Information, Professional". Archived from the original on 3 May 2016. Retrieved 14 May 2016.
Lemke TL, Williams DA (2008). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. p. 675. ISBN 9780781768795. Archived from the original on 8 September 2017.
Kalgutkar AS, Nguyen HT (September 2004). "Identification of an N-methyl-4-phenylpyridinium-like metabolite of the antidiarrheal agent loperamide in human liver microsomes: underlying reason(s) for the lack of neurotoxicity despite the bioactivation event". Drug Metabolism and Disposition. 32 (9): 943–52. PMID 15319335. Archived from the original on 8 September 2017.
"Anticholinergic Cognitive Burden Scale" (PDF). Archived from the original (PDF) on 7 March 2018. Retrieved 23 September 2017.
Florey K (1991). Profiles of Drug Substances, Excipients and Related Methodology, Volume 19. Academic Press. p. 342. ISBN 9780080861142. Archived from the original on 14 January 2023. Retrieved 18 May 2016.
"Compound Report Card". Archived from the original on 11 August 2016. Retrieved 23 June 2016.
"IMODIUM FDA Application No.(NDA) 017694". U.S. Food and Drug Administration (FDA). 1976. Archived from the original on 13 August 2014. Retrieved 5 September 2014.
"IMODIUM A-D FDA Application No.(NDA) 019487". U.S. Food and Drug Administration (FDA). 1988. Archived from the original on 13 August 2014. Retrieved 5 September 2014.
"Loperamide: voluntary withdrawal of infant fomulations" (PDF). WHO Drug Information. 4 (2): 73–74. 1990. Archived from the original (PDF) on 7 September 2014. Retrieved 6 September 2014. The leading international supplier of this preparation, Johnson and Johnson, has since informed WHO that having regard to the dangers inherent in improper use and overdosing, this formulation (Imodium Drops), was voluntarily withdrawn from Pakistan in March 1990. The company has since decided not only to withdraw this preparation worldwide but also to remove all syrup formulations from countries where WHO has a programme for the control of diarrhoeal diseases.
Consolidated List of Products Whose Consumption And/or Sale Have Been Banned, Withdrawn, Severely Restricted Or Not Approved by Governments, 8th Issue. United Nations. 2003. pp. 130–131. ISBN 978-92-1-130230-1. Archived from the original on 8 September 2017.
"IMODIUM MULTI-SYMPTOM RELIEF FDA Application No.(NDA) 020606". U.S. Food and Drug Administration (FDA). 1997. Archived from the original on 13 August 2014. Retrieved 5 September 2014.
"Drug Approval Package: Imodium Advanced (Loperamide HCI and Simethicone NDA #21-140". U.S. Food and Drug Administration (FDA). 24 December 1999. Archived from the original on 2 September 2023. Retrieved 16 December 2020.
"Scherer announces launch of another product utilizing its Zydis technology". PR Newswire Association LLC. 9 November 1993. Archived from the original on 30 August 2014. Retrieved 30 August 2014.
"Anti-diarrhoea drug drives cancer cells to cell death – Aktuelles aus der Goethe-Universität Frankfurt". aktuelles.uni-frankfurt.de. Archived from the original on 23 December 2020.
Mediators and Drugs in Gastrointestinal Motility II: Endogenous and Exogenous Agents. Springer Science & Business Media. 6 December 2012. pp. 290–. ISBN 978-3-642-68474-6. Archived from the original on 12 January 2023. Retrieved 18 May 2016.
Guarino B (4 May 2016). "Abuse of diarrhea medicine you know well is alarming physicians". Washington Post. Archived from the original on 6 May 2016. Retrieved 6 May 2016.
McGinley L (30 January 2018). "FDA wants to curb abuse of Imodium, 'the poor man's methadone'". Washington Post. ISSN 0190-8286. Archived from the original on 30 January 2018. Retrieved 30 January 2018.
Office of the Commissioner. "Safety Alerts for Human Medical Products - Imodium (loperamide) for Over-the-Counter Use: Drug Safety Communication - FDA Limits Packaging To Encourage Safe Use". U.S. Food and Drug Administration (FDA). Archived from the original on 8 April 2018. Retrieved 2 February 2018.

who.int

apps.who.int

"Loperamide: voluntary withdrawal of infant fomulations" (PDF). WHO Drug Information. 4 (2): 73–74. 1990. Archived from the original (PDF) on 7 September 2014. Retrieved 6 September 2014. The leading international supplier of this preparation, Johnson and Johnson, has since informed WHO that having regard to the dangers inherent in improper use and overdosing, this formulation (Imodium Drops), was voluntarily withdrawn from Pakistan in March 1990. The company has since decided not only to withdraw this preparation worldwide but also to remove all syrup formulations from countries where WHO has a programme for the control of diarrhoeal diseases.

worldcat.org

search.worldcat.org

World Health Organization (2014). The selection and use of essential medicines: report of the WHO Expert Committee, 2013 (including the 18th WHO model list of essential medicines and the 4th WHO model list of essential medicines for children). Geneva: World Health Organization. hdl:10665/112729. ISBN 9789241209854. ISSN 0512-3054. WHO technical report series;985.
Connelly D (April 2017). "A breakdown of the over-the-counter medicines market in Britain in 2016". The Pharmaceutical Journal. 298 (7900). Royal Pharmaceutical Society. doi:10.1211/pj.2017.20202662. ISSN 2053-6186.
McGinley L (30 January 2018). "FDA wants to curb abuse of Imodium, 'the poor man's methadone'". Washington Post. ISSN 0190-8286. Archived from the original on 30 January 2018. Retrieved 30 January 2018.